

Search the GenomeWeb Intelligence Network
Advanced Search

GO



- GenomeWeb Daily News
- NEWSLETTERS
- BioArray News
- Biotech Transfer Week
- BioInform
- BioRegion News
- Cell-Based Assay News
- In Sequence
- PGx Reporter
- ProteoMonitor
- RNAi News

GENOME TECHNOLOGY
Genome Technology
Online - The Daily Scan



Open platform...



- UTILITIES
- Feedback
- My Account
- Advertising
- Reprints & Permissions
- Contact
- About
- Privacy
- Site Licenses

PERCEPTION PARTNERS
IP Analytics ▶ Discovery ▶ Value Realization

Patent analytics to scout to identify licensees and prove
[What a novel and valid offering for Bio]

Tech Transfer White Paper Authors Hope to Spur Debate, Socially Responsible Licensing

[March 19, 2007]

By [Ben Butkus](#)

This article has been updated from a previous version, which incorrectly stated that the socially responsible licensing program began at Stanford, rather than UC Berkeley.

Earlier this month, a group of leading US research universities and members of the Association of American Medical Colleges released a set of guidelines for universities and non-profit research institutes to consider when licensing internally developed technologies to private parties.

The white paper, entitled "In the Public Interest: Nine Points to Consider in Licensing University Technology," is thought to be the first document from members of the tech-transfer community that suggests a set of good practices.

"We thought it was really a time to go back to fundamentals, and think about what the values are that really should drive university technology management," Arthur Bienenstock, special assistant to the president for federal research policy at Stanford University and primary organizer of the white paper authors, said last week.

The paper aims to trigger discourse that might strengthen the field, but also comes at a time when technology transfer and the Bayh-Dole legislation that enables it have come under especially heavy fire from critics – which is another major reason the collective felt compelled to draft the document, Bienenstock said.

The white paper grew out of a meeting on Stanford's campus last July, which brought together university research officers and technology-licensing directors from leading US research institutions. In addition to Stanford, the paper was signed by the California Institute of Technology; Cornell University; Harvard University; Massachusetts Institute of Technology;

W
P
A
R

Check unmatched inventions
Visit warf.org

In This Week's Issue

[Washington Life Sci Dis in Project Grants to St](#)

[Emory, UAB Stand to E Dispute Decisions](#)

the University of California system; the University of Illinois, Chicago and UI-Urbana-Champaign; University of Washington; Wisconsin Alumni Research Foundation; and Yale University; as well as the AAMC.

[Bayh-Dole Still Alive and Producing the Intended](#)

The full paper can be seen [here](#).

[North Carolina Biotech](#)
[Aldagen, BASF, Targac](#)
[Exeter Life Sciences, S](#)
[UTMB-Galveston, Genc](#)
[Planck, Miraculins, Mo](#)
[Product Development,](#)
[ImQuest, University of](#)
[Miriam Hospital/Brown](#)
[Pittsburgh, Hiberna, Cl](#)

According to Bienenstock, who is a former vice provost and dean of research and graduate policy at Stanford, several sources of criticism spurred him and Kathy Ku, Stanford director of technology licensing, to organize the group that produced the paper.

One was criticism by freelance journalist Jennifer Washburn "that universities were coming too close to industry in inappropriate manners," Bienenstock said. Washburn has penned multiple critical articles of university tech transfer, and in 2005 authored the book *University, Inc.: The Corporate Corruption of Higher Education*.

[Tony Armstrong, Mark](#)
[Canada, Douglas Woc](#)

"On the other side, you had business people saying that universities were very difficult of intellectual property," Bienenstock added. "[Another reason] was that rumors were rife that university leaders were pressuring university technology managers to maximize income without the other values involved."

Bienenstock also cited ongoing issues that arose around the Wisconsin Alumni Research Foundation that universities "take licenses to do research on certain aspects of human stem cells." He outlined some of those restrictions and clarified its policies on its stem cell IP (see [BTW, 3/5/2006](#)) to make clear that this was a particular sticking point.

"As a senior research officer having real responsibility for research at [Stanford], I enter with fundamental goals," he said. "First, I wanted to ensure that universities and other non-profits do research and advance scientific ... fields associated with university-held property. That university should hinder another from doing research because of intellectual property."

The white paper is not meant to defend the practice of tech transfer, according to Bienenstock, whose aim is to spur discourse that might strengthen the field.

"Different people will take different items" from the guidelines, he said. "I find myself wading through the relevant literature about these points that other people feel strongly about. I'm hoping Jennifer Washburn will write and criticize [the white paper]."

"In these cases, when you're getting down to fundamentals, it's important to have discussions with all concerned parties," Bienenstock added. "So I'm hoping that people will take it up in the future as an opportunity to think about the criticism we've received."

Carol Mimura, assistant vice chancellor for intellectual property and industry research at the University of California, Berkeley, and one of the paper's co-authors, told *BTW* that Bienenstock and his colleagues emphasized transparency in the way universities managed their IP – more understanding, in general, of both public and private, how to manage their IP.

"There are manuals published by [the Association for University Technology Managers] for university practitioners, but from a manager's point of view, there are separate issues to discuss concerning the process of transacting licenses and funded research agreements," Mimura added.

A Social Compact?

One of the most important of those issues, Mimura said, was to stress the role that universities play in science for the greater good.

Mimura authored the section of the guidelines that calls for tech-transfer officials to ensure profit research institutes honor their "social compact with society," help "advance knowledge" and "manage the deployment of resulting innovations for the public benefit."

The guidelines come at a time when technology transfer and the Bayh-Dole legislation that enables it is under especially heavy fire from critics – which is another major reason the collective felt compelled to draft the document.

For example, universities "should strive to create arrangements in ways that ensure that ... and low- or no-cost access to adequate quantities of innovations," Mimura wrote.

Such a philosophy, however, seems to be at the core of a university tech-transfer office: to maximize research investment by bringing in as much revenue as possible.

But these two goals do not have to be mutually exclusive. As an example, she offered what she called a socially responsible licensing program at UC-Berkeley that emerged from the university's property management offices restructured after the 2004 merger.

The resulting reorg combined the office that negotiates incoming corporate-sponsored research agreements with the office that negotiates outgoing IP licensing.

The move "resulted in a different definition of tech-transfer success," Mimura said. "At Berkeley, 'success in all aspects of the industry-university relationship,' including foundation support, revenue that comes in from outlicensing IP, and then research obtained through the program."

Furthermore, the new structure allowed Berkeley to be part of a much-ballyhooed public-private partnership in 2004 to develop a malaria cure, and which Mimura said has served as the poster child for socially responsible licensing.

As part of that deal, the Bill and Melinda Gates Foundation awarded \$42.6 million to nonprofit OneWorld Health to collaborate with Berkeley and its spin-off, Amyris Biotechnologies, to develop a malaria vaccine.

"It's clear that while we were sort of driving the transaction with the lure of a royalty-free license for the developing world, at the end of the day Berkeley was able to get [some] \$8 million for basic research, which we wouldn't have had an opportunity to get from a federal funding agency," she explained. "When your tech-transfer program is open to new definitions of success, it changes the way you measure success, including revenue coming in from the sponsored research side."

"Since we have combined those two units, a given transaction that used to be at the expense of the other, for instance, if it was a royalty-free license, is no longer detrimental because there is a balance through the opposite office that brings in revenue, and it's all good for Berkeley," she said.

Still, Mimura said it was important for those in tech transfer to realize that a possible financial loss from the Berkeley-Gates partnership is not the main reason to have a socially responsible licensing program.

"A program where you use royalty-free license agreements or a commitment to maximize research investment for the developing world doesn't have to be set up to ensure you don't lose money," she said. "It's imperative to do it. We really are trying to maximize our impact, not maximize the revenue."

<p>Biotech Firms Let Employers Fight Over You. You're in Control. Custom Job Match</p> <p>V V</p>

<p>IP and Patent Valuation Expertly assess risks, value in IP transactions and investments</p> <p>V V</p>

<p>Biotech Access Co Build Lists</p> <p>V V</p>

Copyright © 2008 GenomeWeb LLC. All rights reserved.

